You must be 18 or older — and of legal age in your province — to enter. All products are sold strictly for laboratory research use only and are not for human or veterinary consumption.
By entering you confirm you are a qualified buyer of research materials and agree to our Terms and Research-Use Policy.
Articles on CJC-1295, the GHRH analogue studied with and without DAC, and on sourcing it in Canada for laboratory use.
How a peptide signal outside a cell becomes a response inside it: adenylyl cyclase, cyclic AMP, protein kinase A and CREB, why GHRH analogues and growth hormone secretagogues use different routes, and what the cascade diagram leaves out.
The inhibitory half of the growth hormone axis: what somatostatin is, the five receptors it works through, why its three-minute half-life produced octreotide, and why the claim that GHRPs suppress it is not supported.
What each half of the CJC-1295 and ipamorelin pair is, where the synergy argument actually comes from, why no study has tested this combination, and how to verify two peptides in one vial.
CJC-1295 with DAC explained: the Montreal-made GHRH analogue that binds albumin and what the 2006 human studies found.
Why natural peptides vanish in minutes and engineered ones last days: amino-acid swaps, fatty-acid lipidation, albumin binding, DAC, PEGylation and D-amino acids explained.
Growth hormone peptides explained: GHRH analogues vs ghrelin mimetics, how CJC-1295, ipamorelin, tesamorelin and GHRPs compare, and sourcing in Canada.
CJC-1295 vs ipamorelin: a GHRH analogue versus a ghrelin-receptor agonist, DAC vs no DAC, what the human studies found, and sourcing in Canada.